ADAP Advocacy Proposes Transfer of 340B Drug Pricing Program Oversight to CMS

Structured Digest of the Announcement

ADAP Advocacy has released a policy paper calling for the oversight of the 340B Drug Pricing Program to transition from the Health Resources and Services Administration (HRSA) to the Centers for Medicare and Medicaid Services (CMS). The organization argues that current regulatory frameworks are insufficient to ensure that covered entities utilize program revenues to expand patient access as intended by federal law. This proposal seeks to increase transparency and enforcement regarding how hospitals and clinics manage the financial benefits derived from the program.

Key Digest

10 Essential Facts at a Glance

ADAP Advocacy is calling for the 340B Drug Pricing Program oversight to move from HRSA to CMS.
The 340B program is currently the second-largest federal prescription drug program in the United States.
The program requires pharmaceutical companies to sell outpatient drugs to covered entities at discounted prices.
Covered entities are statutorily required to reinvest 340B savings into access for low-income or underserved patients.
HRSA reported that 340B drug sales totaled over $100 billion in 2025.
Hospitals accounted for more than 79% of all 340B drug purchases in 2025.
ADAP Advocacy claims that current HRSA oversight lacks sufficient transparency and enforcement mechanisms.
Existing rules do not require all covered entities to disclose how 340B revenues are spent.
Research by ADAP Advocacy found that 41 of 98 analyzed hospitals reduced charity care spending by 50% or more after joining the 340B program.
The 340B program was originally established under section 602 of the 1992 Veteran's Health Care Act.

What This Means

The 340B Drug Pricing Program, established by the Veteran's Health Care Act of 1992, requires pharmaceutical manufacturers to provide outpatient drugs to specific covered entities at discounted rates. These entities are then expected to reinvest the savings into services for low-income or underserved populations. However, the program has faced increasing scrutiny as its scale has expanded to over $100 billion in annual sales. Critics argue that the current oversight structure, managed by HRSA, lacks the necessary enforcement mechanisms to ensure that hospitals and other participants adhere to the program's original legislative intent. By proposing a shift to CMS, advocates suggest that the program could benefit from more robust regulatory infrastructure, similar to that used for other federal healthcare initiatives.

If implemented, a transition to CMS oversight would represent a significant shift in how federal authorities monitor compliance within the 340B landscape. The debate highlights a growing tension between the administrative autonomy of covered entities and the demand for accountability regarding the usage of program-generated revenue. Research indicates variability in how hospitals report charity care expenditures, fueling concerns that the financial benefits of the program may not always align with the goal of improving patient affordability. Future policy discussions will likely focus on whether CMS possesses the capacity to mandate greater financial disclosure and whether such requirements could alter the operational strategies of participating hospitals and clinics across the country.

Questions Worth Watching

What specific regulatory mechanisms would CMS implement that are currently unavailable to HRSA?
How would a transition in oversight affect the operational costs for hospitals currently participating in the 340B program?
Will federal lawmakers pursue legislative changes to mandate increased financial disclosure for all 340B covered entities?

Loading briefing details...